Prolonged treatment of genetically obese mice with conjugated linoleic acid improves glucose tolerance and lowers plasma insulin concentration: possible involvement of PPAR activation by Wargent, Ed et al.
BioMed  Central
Page 1 of 14
(page number not for citation purposes)
Lipids in Health and Disease
Open Access Research
Prolonged treatment of genetically obese mice with conjugated 
linoleic acid improves glucose tolerance and lowers plasma insulin 
concentration: possible involvement of PPAR activation
Ed Wargent1, Matthew V Sennitt1, Claire Stocker1, Andrew E Mayes2, 
Louise Brown2, Jacqueline O'Dowd1, Steven Wang1, 
Alexandra WC Einerhand3, Inge Mohede3, Jonathan RS Arch*1 and 
Michael A Cawthorne1
Address: 1Clore Laboratory for Life Sciences, University of Buckingham, Buckingham, MK18 1EG, UK, 2Biosciences division, Unilever Research, 
Colworth Laboratory, Sharnbrook, Bedfordshire, MK44 1LQ, UK and 3Lipid Nutrition, Loders Croklaan BV, PO Box 4, 1520 AA Wormerveer, The 
Netherlands
Email: Ed Wargent - ed.wargent@buckingham.ac.uk; Matthew V Sennitt - matthew.sennitt@buckingham.ac.uk; 
Claire Stocker - claire.stocker@buckingham.ac.uk; Andrew E Mayes - Andrew.Mayes@Unilever.com; 
Louise Brown - louise.brown@unilever.com; Jacqueline O'Dowd - jacqueline.odowd@buckingham.ac.uk; 
Steven Wang - steven.wang@buckingham.ac.uk; Alexandra WC Einerhand - Sandra.Einerhand@croklaan.com; 
Inge Mohede - inge.mohede@unilever.com; Jonathan RS Arch* - jon.arch@buckingham.ac.uk; 
Michael A Cawthorne - mike.cawthorne@buckingham.ac.uk
* Corresponding author    
Abstract
Background: Studies in rodents and some studies in humans have shown that conjugated linoleic acid (CLA), especially its trans-
10, cis-12 isomer, reduces body fat content. However, some but not all studies in mice and humans (though none in rats) have
found that CLA promotes insulin resistance. The molecular mechanisms responsible for these effects are unclear, and there are
conflicting reports on the effects of CLA on peroxisomal proliferator-activated receptor-γ (PPARγ) activation and expression.
We have conducted three experiments with CLA in obese mice over three weeks, and one over eleven weeks. We have also
investigated the effects of CLA isomers in PPARγ and PPARα reporter gene assays.
Results: Inclusion of CLA or CLA enriched with its trans-10, cis-12 isomer in the diet of female genetically obese (lepob/lepob)
mice for up to eleven weeks reduced body weight gain and white fat pad weight. After two weeks, in contrast to beneficial effects
obtained with the PPARγ agonist rosiglitazone, CLA or CLA enriched with its trans-10, cis-12 isomer raised fasting blood glucose
and plasma insulin concentrations, and exacerbated glucose tolerance. After 10 weeks, however, CLA had beneficial effects on
glucose and insulin concentrations. At this time, CLA had no effect on the plasma TNFα concentration, but it markedly reduced
the plasma adiponectin concentration. CLA and CLA enriched with either isomer raised the plasma triglyceride concentration
during the first three weeks, but not subsequently. CLA enriched with its trans-10, cis-12 isomer, but not with its cis-9, trans-11
isomer, stimulated PPARγ-mediated reporter gene activity; both isomers stimulated PPARα-mediated reporter gene activity.
Conclusions: CLA initially decreased but subsequently increased insulin sensitivity in lepob/lepob mice. Activation of both PPARγ
and PPARα may contribute to the improvement in insulin sensitivity. In the short term, however, another mechanism, activated
primarily by trans-10,  cis-12-CLA, which probably leads to reduced adipocyte number and consequently reduced plasma
adiponectin concentration, may decrease insulin sensitivity.
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Background
The term conjugated linoleic acid (CLA) refers to a mix-
ture of positional and geometric isomers of linoleic acid
(cis-9, cis-12-octadienoic acid). The major components of
CLA, are the cis-9, trans-11 (c9, t11) and the trans-10, cis-
12 (t10, c12) isomers, both of which have biological activ-
ities. The t10, c12-isomer is the one primarily responsible
for the effects of CLA on weight gain and insulin sensitiv-
ity. The CLA used in the present study contains these iso-
mers in roughly equal proportions.
CLA may be of benefit in cancer, atherosclerosis and pos-
sibly some disorders of the immune system. In addition,
it reduces weight gain and fat accretion in rats and mice.
Some studies have found that CLA causes fat loss in
humans [1-4], and two studies have shown weight
loss[2,5], but another did not find any significant effect of
CLA on body composition or body weight [6]. More
marked effects of CLA on body weight and body compo-
sition have been obtained in rats and especially mice, pos-
sibly because the rate of energy expenditure relative to
energy stores is much higher in rodents than in humans.
In previous studies, CLA or t10, c12-CLA has exacerbated
glucose tolerance and raised plasma insulin levels in nor-
mal and genetically obese (lepob/lepob) mice, despite caus-
ing weight loss [7-10]. Both t10, c12-CLA and c9, t11-CLA
have also been reported to cause insulin resistance in
humans [11-13], although in other studies neither CLA
nor its major isomers affected insulin resistance signifi-
cantly [14-17]. By contrast, CLA or t10, c12-CLA
improved glucose tolerance in Zucker fatty lepfa/lepfa and
Zucker diabetic fatty lepfa/lepfa rats [18-21]. One difference
between the rodent species is that peroxisomal prolifera-
tor-activated receptor (PPAR)α-regulated genes are more
responsive to CLA in mice than in rats [22], but this would
be expected to correlate with improved insulin sensitivity
in mice rather than rats [23].
By contrast with this result for PPARα knockout mice, at
least one response to CLA depends on expression of
PPARγ: the beneficial effect of CLA in a mouse model of
colitis was absent in mice that lacked PPARγ in the colon
[24]. In view of the variety of reports of CLA's effects on
PPARγ activity and expression, it is possible that PPARγ
responses may vary between species; the different propor-
tions of isomers in the CLA used in different studies may
also be important [25]. Some reports describe activation
of PPARγ by CLA or t10, c12-CLA [18,33]; others describe
little or no agonist activity [10], but antagonism of rosigl-
itazone [25,27]. One report describes increased expres-
sion of PPARγ mRNA in white adipose tissue of rats [28]
and another describes increased expression in liver of
mice [10], but studies in isolated adipocytes or of adipose
tissue from treated mice show decreased expression
[25,27,29,30].
Since PPARγ agonists increase insulin sensitivity but pro-
mote adipogenesis, decreased activity of PPARγ in adipose
tissue could explain why CLA reduces obesity but
increases insulin resistance. Various other mechanisms
have also been suggested to explain why CLA exacerbates
insulin sensitivity despite causing loss of fat. One of these
is increased expression of tumour necrosis factor (TNF)α,
since TNFα is associated with apoptosis of adipocytes but
causes insulin resistance. TNFα mRNA levels were mark-
edly increased in isolated adipocytes from normal mice
that had been fed on CLA for as little as four days [8]. Sur-
prisingly however, serum TNFα levels were reduced by
CLA in both normal rats [31] and mice [32]. Moreover
CLA reduced the expression of TNFα in mouse macro-
phages [33].
Although most studies in mice have found that CLA exac-
erbates glucose tolerance and raises the plasma insulin
concentration, in one study treatment of lepdb/lepdb mice
with CLA for eleven weeks improved glucose tolerance
and reduced plasma insulin concentration during the glu-
cose tolerance test, indicating improved insulin sensitiv-
ity. Treatment for five weeks also improved glucose
tolerance but plasma insulin was raised [34]. It is some-
times difficult to interpret studies in lepdb/lepdb  mice
because β-cell failure as well as insulin resistance affects
glucose homeostasis, and glycosuria can cause weight
loss. Therefore, to investigate the effect of CLA on glucose
homeostasis further, we have conducted four experiments
in lepob/lepob mice. We have included rosiglitazone as a
comparator in one experiment and compared the effects
of t10, c12- and c9, t11-enriched CLA with CLA in another
experiment. The first three experiments were over 22 days,
whereas the fourth was extended to eleven weeks and
included measurements of plasma TNFα and adiponec-
tin. An intriguing finding is that whereas CLA initially
exacerbated glucose tolerance and raised the plasma insu-
lin level, after ten weeks it began to improve glucose toler-
ance and lower the plasma insulin levels.
We also describe activation of PPARγ by t10, c12 but not
by c9, t11-CLA, whereas PPARα was activated by both
isomers.
Results
Weight gain
Inclusion of CLA in the diet of genetically obese (lepob/
lepob) mice reduced their body weight, or weight gain com-
pared to mice fed on a diet containing a similar amount
of sunflower oil (Figure 1). Mice fed on chow supple-
mented with sunflower oil gained weight at the same rate
as mice fed on chow alone (Figure 1b). The effect of CLALipids in Health and Disease 2005, 4:3 http://www.lipidworld.com/content/4/1/3
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on weight gain appears to be primarily due to t10, c12-
CLA, since CLA enriched to 90% with this isomer had
more effect on weight gain than CLA containing 50% t10,
c12-CLA and 50% c9, t11-CLA (Figure 1c). CLA that was
enriched to 90% with the c9, t11 isomer had only a small
effect on weight gain, and this may have been due to the
10% t10, c12-CLA. Food intake was measured over two
days in experiment 4 and was not reduced by CLA (food
intake per group: control, 33.1 and 37.5 g; CLA 10 g/kg
diet, 35.1, 43.4 g; CLA 25 g/kg diet, 39.9, 39.6). Rosiglita-
zone (10 mg/kg diet) reduced body weight (Figure 1a) but
to a lesser extent than CLA (15 g/kg diet).
Tissue weights and body length
The weight of the parametrial white fat pads was reduced
by CLA and by CLA enriched with t10, c12- but not c9,
t11-CLA (Tables 1 and 2). The weight of the interscapular
brown fat pad was reduced by CLA in experiment 4 (Table
2) but not in experiment 3 (Table 1). This may be because
experiment 4 lasted for 11 weeks, whereas experiment 3
lasted for only 3 weeks and the control brown fat pad was
more than three times heavier at the end of experiment 4
than at the end of experiment 3, presumably due prima-
rily to its lipid content.
Liver weight was increased by CLA and by CLA enriched
with either isomer, c9, t11-enriched CLA having the small-
est effect. The weight of the pancreas was unaffected by all
treatments (Tables 1 and 2). Others have reported that
t10, c12- and c9, t11-CLA increase liver weight in lean
mice, the effect of the t10, c12 isomer being associated
with increased liver lipid [35].
Weight gain in mice fed on diets that contained (doses per kg diet). (a) experiment 1: sunflower oil (● , 15 g), rosiglitazone (,  10 mg), CLA (▲ , 15 g); (b) experiment 2: chow only (❍ ), sunflower oil (● , 25 g), CLA (▲ , 25 g); (c) experiment 3: sunflower  oil (● , 25 g), CLA (▲ , 25 g), t10, c12-CLA (, 25g), c9, t11-CLA (Ќ, 25 g); (d) experiment 4: sunflower oil (● , 25 g), CLA (10  g) plus sunflower oil (15 g) (■ ), CLA (▲ , 25 g) Figure 1
Weight gain in mice fed on diets that contained (doses per kg diet) (a) experiment 1: sunflower oil (● , 15 g), rosiglitazone 
(,10 mg), CLA (▲ , 15 g); (b) experiment 2: chow only (❍ ), sunflower oil (● , 25 g), CLA (▲ , 25 g); (c) experiment 3: sun-
flower oil (● , 25 g), CLA (▲ , 25 g), t10, c12-CLA (, 25 g), c9, t11-CLA (Ќ, 25 g); (d) experiment 4: sunflower oil (● , 25 g), 
CLA (10 g) plus sunflower oil (15 g) (■ ), CLA (▲ , 25 g). *P < 0.05; **P < 0.01: ***P < 0.001 compared to sunflower oil group.
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Body length was reduced by CLA (Table 2).
Glucose tolerance
Rosiglitazone lowered fasting blood glucose, improved
glucose tolerance (Figure 2a) and reduced the area under
the glucose tolerance curve (Figure 3a). Two weeks treat-
ment with CLA or with CLA enriched with t10, c12-CLA
raised fasting blood glucose, exacerbated glucose toler-
ance (Figures 2b to 2d) and increased the area under the
glucose tolerance curve (Figures 3b to 3d) compared to
the sunflower oil and chow alone diets. CLA-enriched
with c9, t11-CLA had no effect (Figures 2c and 3c).
After five weeks of treatment the higher dose of CLA raised
glucose levels less than it had after two weeks (Figures 2d,
e; 3d, e), and after 10 weeks this dose actually improved
glucose tolerance (Figure 2f) and reduced the area under
the glucose tolerance curve (Figure 3d). Its effect was sim-
ilar to that of rosiglitazone over two weeks in experiment
1 (Figures 2a and 3a). The lower dose reduced the peak
glucose level after 10 weeks, but it did not reduce the area
under the glucose tolerance curve significantly.
Insulin
The improvement in glucose tolerance in response to ros-
iglitazone was associated with a reduction in the fasting
plasma insulin level, but rosiglitazone did not reduce the
terminal fasting insulin level (Figure 4a). The exacerba-
tions of glucose tolerance in response to two weeks treat-
ment with CLA and CLA enriched with t10, c12-CLA were
associated with increases in the fasting plasma insulin
level. CLA enriched with c9, t11-CLA did not alter the
fasting insulin level on the day that it showed no effect on
glucose tolerance. However, c9, t11-enriched CLA
increased the plasma insulin level in fed mice on day 21
(Figure 4c).
After five weeks both doses of CLA still raised the fasting
plasma insulin level, but after ten weeks, both doses
reduced the plasma insulin level compared to the control
group (Figure 4d).
Insulin resistance
A useful indicator of insulin resistance can be obtained by
multiplying values for fasting blood glucose and plasma
Table 1: Terminal tissue weights and NEFA levels in experiment 3. NEFA levels were measured in 5h-fasted mice on day 13. 
Termination was on day 22. Supplements were included in the diet at concentrations of 25 g/kg.
Sunflower oil CLA t10, c12-CLA c9, t11-CLA
White adipose wt (g) 0.95 ± 0.12 0.49 ± 0.05+ 0.39 ± 0.06+ 0.82 ± 0.04
Brown adipose wt (g) 0.21 ± 0.03 0.23 ± 0.02 0.27 ± 0.11 0.18 ± 0.03
Liver wt (g) 2.02 ± 0.15 3.17 ± 0.05+ 3.25 ± 0.10+ 2.76 ± 0.18+
Pancreas wt (g) 0.12 ± 0.02 0.12 ± 0.01 0.11 ± 0.02 0.20 ± 0.02
NEFA (mM) 1.09 ± 0.09 1.13 ± 0.14 0.90 ± 0.07 0.82 ± 0.11
+ P < 0.001; n = 6
Table 2: Terminal tissue weights and plasma hormones and NEFA levels in experiment 4. NEFA levels were determined in 5h-fasted 
mice on the days shown. Other measurements were in fed mice on day 77.
Sunflower oil 1% Clarinol A80 2.5% Clarinol A80
Body length (mm) 95.0 ± 1.0 85.7 ± 0.3+ 86.4 ± 1.4+
White adipose wt (g) 2.11 ± 0.15 0.63 ± 0.07+ 0.19 ± 0.02+
Brown adipose wt (g) 0.74 ± 0.07 0.33 ± 0.04+ 0.007 ± 0.005+
Liver wt (g) 4.96 ± 0.17 6.27 ± 0.58 6.77 ± 0.36*
Pancreas wt (g) 0.18 ± 0.01 0.20 ± 0.01 0.16 ± 0.02
NEFA (mM)
Day 14 3.20 ± 0.17 3.58 ± 0.07 3.27 ± 0.13
Day 35 3.46 ± 0.42 3.93 ± 0.22 2.82 ± 0.40
Day 70 2.90 ± 0.19 3.44 ± 0.13* 1.92 ± 0.09+
Plasma adiponectin (ng/ml) 35.6 ± 7.0 8.2 ± 1.2+ 0.89 ± 0.13+
Plasma TNFα (pg/ml) 34.0 ± 5.7 33.0 ± 2.4 42.3 ± 7.1
* P < 0.05; + P < 0.001; n = 6Lipids in Health and Disease 2005, 4:3 http://www.lipidworld.com/content/4/1/3
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insulin concentrations [36]. This is analogous to
homeostatic model assessment (HOMA), which has been
developed for studies in humans, although the full ver-
sion, which originally involved dividing the product of
glucose (mM) and insulin (mU/ml) concentrations by
22.5 is not suitable for studies in rodents [37]. By multi-
plying fasting blood glucose (mM) by plasma insulin
(nM) we illustrate in Figure 5 how CLA initially exacer-
bated but subsequently improved insulin resistance.
Triglycerides and fatty acids
CLA raised the fasting triglyceride level in experiments 1
to 3 (Figures 6a to 6c), but in experiment 4 the only
statistically significant effect was an increase elicited by
the lower dose after two weeks (Figure 6d). CLA enriched
with t10, c12-CLA had a similar or greater effect than CLA.
Surprisingly on day 13 c9, t11-CLA, but not CLA or t10,
c12-CLA caused a significant increase in the plasma trig-
lyceride level, although c9, t11-CLA did not have a signif-
icant effect compared to CLA (Figure 6c).
CLA and isomer-enriched CLAs had no effect on the fast-
ing plasma non-esterified fatty acid (NEFA) concentration
in experiment 3 (Table 1), and CLA had no effect after two
and five weeks in experiment 4 (Table 2). After ten weeks,
however, the lower dose of CLA raised the plasma concen-
tration of NEFA, whereas the higher dose lowered it (Table
2).
TNFα and adiponectin
After ten weeks CLA had no effect on the plasma TNFα
concentration. The plasma adiponectin concentration, by
contrast, was markedly decreased (Table 2).
PPAR activation
CLA enriched with t10, c12-CLA (50 and 100 µM), but
not with c9, t11-CLA, stimulated PPARγ-mediated
reporter gene activity (Figure 7a). In contrast, both CLA
isomers (100 µM) elicited a significant increase in PPARα-
mediated reporter gene expression, and c9, t11-CLA was
effective at 10 µM (Figure 7b).
Oral glucose tolerance Figure 2
Oral glucose tolerance. Symbols are the same as in Figure 1 and again (a) is experiment 1, (b) is experiment 2 and (c) is exper-
iment 3. (d), (e) and (f) are oral glucose tolerance curve on days 14, 35 and 70 for experiment 4.
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Discussion
Physiology
A number of studies have found that CLA reduces weight
gain and fat accretion in both rats and mice. Those that
have failed to show such effects are generally those that
have used low levels of CLA or CLA that contained low
concentrations of t10, c12-CLA [6]. Studies disagree, how-
ever, as to whether CLA improves or exacerbates glucose
tolerance and insulin resistance in these species: studies in
rats show improvements [18-21], whereas studies in mice,
with the exception of one study in lepdb/lepdb mice [34],
show exacerbations [7-10]. In humans, several studies
have shown a loss of fat [1-4], but doubts have been raised
about the use of CLA for the treatment of obesity by
reports that both t10, c12-CLA and c9, t11-CLA exacer-
bated insulin resistance in abdominally obese men [11-
13], and that t10, c12- (but not c9, t11-CLA) reduced the
HDL cholesterol concentration or the HDL:LDL choles-
terol ratio [11,12,14]. These are by no means consistent
findings, however [13-17].
Our study raises the possibility that an initial exacerbation
of glucose tolerance, apparently due to insulin resistance,
might, after prolonged treatment with a high dose of CLA,
be followed by improved insulin sensitivity and glucose
tolerance. We used genetically obese (lepob/lepob) mice as
Areas under the glucose tolerance curves shown in Figure 2 Figure 3
Areas under the glucose tolerance curves shown in Figure 2. Panel (d) shows areas from Figure 2 (d), (e) and (f). Doses of CLA 
are shown as g/kg diet. *P < 0.05; **P < 0.01: ***P < 0.001 compared to sunflower oil group.
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our model of insulin resistance. There is only one previ-
ous report of the effect of CLA in lepob/lepob mice [9]. In
agreement with other studies in rodents, we found that
CLA reduced weight gain and perigenital fat pad weight,
and that this effect appeared to be produced by the t10,
c12- rather than the c9, t11-isomer. We also found, like
other studies in mice, that glucose tolerance was initially
exacerbated and the plasma insulin concentration was
raised. Again, these effects were primarily due to the t10,
c12-isomer. However, in our last experiment we found
that after ten weeks glucose tolerance improved and the
fasting plasma insulin concentration was reduced by treat-
ment of lepob/lepob mice with CLA. These benefits were
achieved faster with the higher (25 g/kg diet, including
40% t10, c12-CLA) than the lower dose (10 g/kg diet) of
CLA.
Our results are similar to those of Hamura et al [34], inso-
far as they found that treatment of lepdb/lepdb mice with
CLA for eleven weeks improved glucose tolerance and
lowered insulin levels during the glucose tolerance test.
Hamura  et al. found that glucose tolerance was also
improved in lepdb/lepdb mice after five weeks of treatment,
but this was apparently due to increased insulin secretion
rather than improved insulin sensitivity. It is not clear why
others have not also found improved glucose tolerance
Plasma insulin values from (a) experiment 1, (b) experiment 2, (c) experiment 3, and (d) experiment 4 Figure 4
Plasma insulin values from (a) experiment 1, (b) experiment 2, (c) experiment 3, and (d) experiment 4. Doses are described in 
Methods and the legend to Figure 1. In panel (d) the does of CLA are in g/kg diet. Day 13 or 14, day 35 and day 70 values are 
following a 4.5 h fast; day 22 values are following a 16 h fast; and day 21 values are for fed animals. Doses of CLA are shown as 
g/kg diet. *P < 0.05; **P < 0.01: ***P < 0.001 compared to sunflower oil group.
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and reduced insulin levels following prolonged treatment
of mice with CLA. In the one previous study in lepob/lepob
mice, the dose of t10, c12-CLA was only about 5.9 g/kg
diet and treatment was for only four weeks [9]. A study in
lean C57Bl/6J mice similarly used a dose of 4 g/kg diet of
t10, c12-CLA for four weeks [10]. Other studies lasted for
twelve weeks and eight months, however. The dose of CLA
was only 10 g/kg diet in both studies and neither was con-
ducted in exceptionally obese or insulin resistant mice
[7,8]. We therefore suggest that improved insulin sensitiv-
ity is most likely to be found when mice are initially mark-
edly obese and insulin resistant, and when treatment is
prolonged and results in a major loss of adipose tissue.
The relevance of our findings to humans is unclear, but it
is interesting that in one 12 month study plasma glucose
was raised after two weeks treatment with CLA, but not at
any subsequent time [16].
After ten weeks the higher dose of CLA lowered the
plasma fasting non-esterified fatty acid concentration,
which is consistent with improved insulin sensitivity
(Table 2). The lower dose raised the NEFA concentration
at this time, despite apparently improving insulin sensi-
tivity, even though it did not raise the NEFA concentration
at earlier times when glucose tolerance was reduced and
plasma insulin levels were raised. This paradox seems to
be largely a consequence of the low control NEFA
concentration after ten weeks: the highest NEFA level in
the low dose CLA group was after five weeks of treatment
and it seems possible that the NEFA concentration in the
low dose group would have fallen with further treatment,
just as it was falling in the high dose group (Table 2).
Hamura  et al. [34] found that after twelve weeks CLA
reduced the plasma NEFA concentration in lepdb/lepdb
mice, suggesting that insulin sensitivity was improved.
Effect of CLA on insulin sensitivity in experiment 4 Figure 5
Effect of CLA on insulin sensitivity in experiment 4. The insulin sensitivity index was determined by multiplying the fasting 
blood glucose concentration (Figure 2d, e, f, 0 min) by the fasting plasma insulin concentration (Figure 4d).
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After six weeks, however, CLA raised the NEFA
concentration, suggesting that CLA exacerbated insulin
sensitivity at this time. The elevated plasma NEFA concen-
tration may have been partly responsible for the elevated
plasma insulin and improved glucose tolerance after six
weeks in their study. CLA and its major isomers have little
or no effect on plasma NEFA levels in humans [11,12,14].
Mechanism
No single mechanism has been identified that can
account for the various effects of CLA on lipid and carbo-
hydrate metabolism, let alone its anticarcinogenic and
immunomodulatory activities. In part this is because CLA
is a mixture of isomers, each with its own balance of activ-
ities. The activities of even the most active isomer, t10,
c12-CLA, cannot, however, be pinned down to a single
mechanism.
We can first rule out any possibility that responses to CLA
in our experiments were mediated by a fall in leptin levels
as has been suggested by others [8], because our study was
conducted in lepob/lepob mice. In any event, when fat loss is
Plasma triglyceride values from (a) experiment 1, (b) experiment 2, (c) experiment 3, and (d) experiment 4 Figure 6
Plasma triglyceride values from (a) experiment 1, (b) experiment 2, (c) experiment 3, and (d) experiment 4. Doses are 
described in Methods and the legend to Figure 1. In panel (d) the does of CLA are in g/kg diet. Day 13 or 14, day 35 and day 70 
values are following a 4.5 h fast; day 22 values are following a 16 h fast; and day 21 values are for fed animals. Doses of CLA are 
shown as g/kg diet. *P < 0.05; **P < 0.01: ***P < 0.001 compared to sunflower oil group.
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achieved by reducing energy intake, insulin action and
glucose tolerance improve despite a reduction in the
plasma leptin concentration.
Antagonism of PPARγ by t10, c12-CLA has been suggested
to contribute to both decreased adipogenesis and insulin
sensitivity [38]. A recent report that c9, t11-CLA exacer-
bates insulin sensitivity [12] is consistent with a report
that it too antagonises PPARγ, albeit a little less effectively
than t10, c12-CLA [25]. We found little evidence that c9,
t11-CLA exacerbates insulin sensitivity in lepob/lepob mice,
however (Figures 3c and 4c), and others have reported no
effect [9].
Some workers favour the hypothesis that t10, c12-CLA
decreases adipogenesis and insulin sensitivity by a mech-
anism that involves decreased expression of PPARγ in adi-
pose tissue [38]. Since PPARγ agonists increase PPARγ
expression in some situations [39,40], antagonism of
PPARγ might decrease PPARγ expression. By contrast with
mice, however, in rats CLA increases both PPARγ mRNA
expression and insulin sensitivity [28]. Thus it is possible
that CLA activates one mechanism that decreases and
another that increases insulin sensitivity, and that PPARγ
expression reflects the balance of these forces, rather than
having a causal role.
In any event, our results do not support antagonism of
PPARγ as a mechanism of action of CLA. In agreement
with some other workers [18,33], we find that t10, c12-
CLA, but not c9, t11-CLA activates PPARγ. Activation of
PPARγ might contribute to the improvement in insulin
sensitivity in lepob/lepob mice following prolonged treat-
ment with CLA.
Activation of PPARα might also contribute to improved
insulin sensitivity. t10, c12-CLA was more potent as an
activator of PPARα than of PPARγ in the particular assays
that we used, although it is inappropriate to make precise
comparisons of potency in view of the different plasmids,
their levels and other differences between the two assays.
In contrast to some previous reports [10,41], t10, c12-CLA
was, if anything, more potent than c9, t11-CLA as an acti-
vator of PPARα. Nevertheless, c9, t11-CLA was sufficiently
Effect of the c9, t11 and t10, c12-enriched CLA on (a) PPARγ- and (b) PPARα mediated gene expression Figure 7
Effect of the c9, t11 and t10, c12-enriched CLA on (a) PPARγ- and (b) PPARα mediated gene expression. Cos-7 cells were 
transiently transfected with the plasmids pPPRE3TK-luc, pRLTK, pRSV/hRXRα and pcDNA3/hPPARγ 1 (a) or pcDNA3/
hPPARα (b). Transfected cells were treated for 46 (a) or 24 (b) hours. Cell extracts were assayed for firefly and renilla luci-
ferase activity. Reporter gene activity was determined by normalising firefly luciferase activity against renilla luciferase activity. 
The CLA isomers were prepared in 0.1% DMSO so that each of the stated isomers was at the given concentration. * P < 0.05 
and ** P < 0.01; n = 6.
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effective to raise the possibility that it contributed to the
improvement in insulin sensitivity due to the prolonged
treatment with CLA.
Activation of PPARα and peroxisomal proliferation might
contribute to the increased liver weight in c9, t11-CLA-
treated mice, steatosis also playing a role, at least in the
case of t10, c12-CLA [10]. Activation of PPARα does not,
however, appear to have a major role in the anti-obesity
effect of CLA, because CLA reduced body fat content in
PPARα knockout mice [42]. Moreover, some investigators
have found that c9, t11-CLA is more effective than t10,
c12-CLA as an activator of PPARα [10,41]. Other workers
have shown that CLA also activates PPARβ/δ [10,41], but
the effect was small in one these studies and c9, t11-CLA
was more potent than t10, c12-CLA [10].
We measured plasma TNFα and adiponectin concentra-
tions following prolonged treatment with CLA. Neither
hormone contributed to the improved insulin sensitivity
at this time: the plasma TNFα concentration was
unchanged by CLA, and the plasma adiponectin concen-
tration was reduced rather than increased. Other investi-
gators have reported that t10, c12-CLA but not c9, t11-
CLA reduces the level of adiponectin mRNA in white
adipose tissue of lean mice [35]. Since adiponectin is
released primarily from adipocytes but plasma levels are
low in obesity and increased by weight loss [43], the
marked reduction in plasma adiponectin in the CLA-
treated mice is consistent with their having less, rather
than smaller, adipocytes. This is in turn consistent with
the view that the anti-obesity effect of CLA and the initial
decrease in insulin sensitivity is due to apoptosis of adi-
pocytes. Decreased fat cell number may also account for
the tendency of CLA to increase plasma triglyceride levels
in lepob/lepob mice, the remaining fat cells being too full
to accommodate the triglyceride released by cells that
have undergone apoptosis. Other workers have reported
that CLA reduces plasma triglyceride levels; but in some
cases this reduction was in lean mice with less replete adi-
pocytes [42,26], and in the one other study in lepob/lepob
mice, it was an effect of c9, t11-CLA, which presumably
causes little apoptosis of adipocytes [9]. Interestingly, CLA
has been reported to increase plasma adiponectin levels in
Zucker diabetic fatty rats, at the same time decreasing
plasma triglycerides and improving insulin sensitivity
[21]. We therefore suggest that the main effect of CLA in
Zucker diabetic fatty rats is to reduce fat cell size, rather
than to promote apoptosis and reduce fat cell number.
Conclusions
Treatment with CLA initially decreased but subsequently
increased insulin sensitivity in lepob/lepob mice. Activation
of both PPARγ and PPARα may contribute to the improve-
ment in insulin sensitivity. In the short term, however,
another mechanism, activated by t10, c12-CLA but not c9,
t11-CLA, which probably leads to reduced adipocyte
number and consequently plasma adiponectin concentra-
tion, may decrease insulin sensitivity.
Methods
Animals
Female C57Bl/6 lepob/lepob mice were obtained from Har-
lan Olac (Bicester, UK) and maintained at 23 ± 1°C with
lights on from 07:00 to 19:00 h. They were housed in plas-
tic cages with bedding and fed 'rat and mouse standard
diet' (Beekay Feed, B & K Universal Ltd., Hull, UK). Six
days before the start of the studies they were allocated to
treatment groups (6 mice per group), such that each group
had a similar mean bodyweight. The CLA and other treat-
ments were mixed with powdered diet and given ad libi-
tum. The mice were killed by cervical dislocation in
experiments 1 to 3; in experiment 4 they were anaesthe-
tised with sodium pentobarbitone (Sagatal; 80 mg/kg,
i.p.) and exsanguinated through an aortic catheter. All
procedures were conducted in accordance with our Home
Office, UK project licence under the Animals (Scientific
Procedures) Act and as agreed by the University of Buck-
ingham Ethical Review Board.
Materials added to diets
CLA (in acid form), including isomer-enriched CLA, and
sunflower oil were provided by Loders Croklaan,
Wormerveer, The Netherlands. The CLA used in experi-
ments 1, 2 and 3 was Clarinol™ A-60, containing 30% c9,
t11-CLA and 31% t10, c12-CLA and 25% oleic acid. The
CLA used in experiment 4 was Clarinol™ A-80, containing
40% c9, t11-CLA and 40% t10, c12-CLA. Rosiglitazone
was synthesised by Dextra Laboratories, Reading, Berks,
UK.
Experiment 1
At the start of treatment the mice weighed 34.5 ± 4.3 g
(mean ± S.D.). The treatment groups were high oleic
(83.5%) sunflower oil (control; 15 g/kg diet); rosiglita-
zone (10 mg/kg diet) plus high oleic sunflower oil (15 g/
kg diet); CLA (Clarinol™ A-60: 15 g/kg diet). An oral glu-
cose tolerance test was conducted after 14 days as
described below. 30 min prior to giving glucose, when the
mice had been fasted for 4.5 hours, blood (100 µl) was
taken for the measurement of plasma insulin and triglyc-
erides. Plasma insulin and triglycerides were also meas-
ured after 21 days when the mice were feeding ad libitum,
and after 22 days when they had been fasted for 16 hours,
immediately before termination of the experiment.
Experiment 2
At the start of the treatment the mice weighed 44.0 ± 3.2 g
(mean ± S.D.). A group fed on powdered chow alone was
included. The doses of CLA (Clarinol™ A-60) and sun-Lipids in Health and Disease 2005, 4:3 http://www.lipidworld.com/content/4/1/3
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flower oil in the other two groups were increased to 25 g/
kg diet. The oral glucose tolerance test and other measure-
ments were carried out as described for experiment 1,
except that the glucose tolerance test was one day earlier
(i.e. after 13 days).
Experiment 3
At the start of treatment the mice weighed 34.1 ± 2.1 g
(mean ± S.D.). The treatment groups were high oleic sun-
flower oil (25 g/kg diet); CLA (Clarinol ™ A-60: 25 g/kg
diet); CLA with the CLA component of Clarinol enriched
to 90% with t10, c12-CLA (25 g/kg diet); similarly, CLA
enriched to 90% with c9, t11-CLA (25 g/kg diet). The oral
glucose tolerance test and other measurements were car-
ried out as described for experiment 2. In addition, the
plasma non-esterified fatty acid concentration was meas-
ured in the blood taken prior to the glucose tolerance test,
and the liver, pancreas, parametrial white adipose tissue
depot and interscapular brown adipose tissue depot were
weighed at termination.
Experiment 4
At the start of treatment the mice weighed 31.6 ± 3.8 g
(mean ± S.D.). The treatment groups were high oleate (as
glyceride) sunflower oil (25 g/kg diet); CLA (Clarinol
A80: 10 g/kg diet) plus high oleic sunflower oil (15g/kg
diet); CLA (Clarinol A80: 25 g/kg diet). Oral glucose tol-
erance tests preceded by blood sampling for the measure-
ment of triglycerides, insulin and non-esterified fatty acids
were taken after 14, 35 and 70 days of treatment. After 77
days of treatment the animals were anaesthetised in the
fed state and blood was taken from the thoracic aorta for
the measurement of plasma TNFα and adiponectin. Tis-
sues were weighed as in experiment 3. Body length was
measured from the tip of the nose to the anus.
Oral glucose tolerance tests
In each experiment oral glucose tolerance was measured
after 13 or 14 days. In experiment 4 it was also measured
after five and ten weeks. The mice were fasted for five
hours before being dosed with glucose (3 g/kg, p.o. in
experiments 1 and 2; 2 g/kg, p.o. in experiments 3 and 4).
Blood samples (20 µl) were taken from the tip of the tail
after applying a local anaesthetic (lignocaine) and imme-
diately before and 30, 60, 90, 120 and 180 min after dos-
ing the glucose. They were mixed with haemolysis reagent
and blood glucose was measured in duplicate using the
Sigma Enzymatic (Trinder) colorimetric method and a
SpectraMax 250 (Molecular Devices Corporation, Sunny-
vale, CA, USA). Areas under the glucose tolerance curve
(0–180 min) and other manipulations and analysis of the
data were carried out using Prism software, version 3.0
(GraphPad Software Inc., San Diego, CA, USA).
Other plasma analytes
Blood was collected into EDTA-coated microcuvettes
(Sarstedt microcuvette, Aktiengsellschaft & Co., Nämbre-
cht, Germany) for the measurement of plasma insulin,
non-esterified fatty acids and triglycerides. Plasma was
stored at -80°C. 5 µl plasma samples were assayed using
kits for triglyceride (Sigma enzymatic colorimetric
method), non-esterified fatty acids (Wako Chemicals,
Neuss, Germany) and insulin (mouse standard; Crystal
Chemistry Incorporated, Downers Grove, IL, USA).
For the measurement of plasma TNFα (Linco; St Charles,
MI, USA) and adiponectin (Biosource UK, Nivelles, Bel-
gium), blood was taken into tubes containing 200 units of
heparin and plasma was stored at -80°C.
Plasmids for reporter gene assays
pRSV/hRXRα and pcDNA3/hPPARγ1 were both obtained
from Professor VKK Chatterjee (Addenbrooke's Hospital,
Cambridge, UK). PPPRE3TK-luc was prepared by replac-
ing the NF-kB enhancer element of pNF-κB-luc (Clon-
tech) with a cassette of 3 PPAR Response Elements
(PPREs). A double-stranded PPRE cassette was prepared
using the 'Klenow fill-in' technique. An 113 bp oligonu-
cleotide (PPRE3) 5'- GCATTCACGCGTCAAATATAG-
GCCATAGGTCATTCTCGAGCAAATATAGGCCATAGGTC
ATTCTCGAGCAAATATAGGCCATAGGTCAGATTCGAT-
CAATATAGGCCATAGGTCACTCGAGGCAACAGATCT-
TACGCATG -3' containing a triplet of PPREs and
appropriate restriction endonuclease sites was used as a
template for synthesis of a second DNA strand. This was
primed by PPRE3R, 5'-CATGCGTAAGATCTGTTGCC-3',
which is complementary to the 3' region of PPRE3. 20 µl
annealed PPRE3 and PPRE3R, 1.5 µl 2 mM dNTPs, 1 ×
Klenow Buffer and 5 units DNA Polymerase I (Klenow
fragment), were incubated for 1 hour at 37°C and then 10
minutes at 75°C, purified by ethanol precipitation and
resuspended in sterile water. The double-stranded PPRE
cassette was digested with MluI and BglII and ligated into
pNF-κ B-luc that had been cleaved with the same restric-
tion endonucleases. Ligated DNA was transformed into
competent JM109, E. coli cells (Promega). pcDNA3/
PPARα was prepared by removing the human PPARα
cDNA insert from pUC18/hPPARα as a NruI/BamHI
fragment and ligating it into EcoRV/BamHI cleaved
pcDNA3.1(-) (Invitrogen). Ligated DNA was transformed
into competent JM109, E. coli cells (Promega).
PPARγ and PPARα reporter gene assays
Cos-7 cells (ECACC No. 87021302) were routinely cul-
tured in DMEM containing 10% FCS, 2 mM L-Glutamine,
100 iu/ml penicillin and 100 µg/ml streptomycin at
37°C/5% CO2. Transient transfections were performed
using LipofectAMINE as directed by the manufacturers
(GibcoBRL). For the PPARγ assay Cos-7 cells were platedLipids in Health and Disease 2005, 4:3 http://www.lipidworld.com/content/4/1/3
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in 24-well plates at a density of 0.375 × 105 cells/well.
Cells were transfected in serum-free medium (DMEM
containing 2 mM L-glutamine) with pPPRE3TK-luc,
pRLTK, pRSV/hRXRα and pcDNA3/hPPARγ 1 at concen-
trations of 0.4, 0.03, 0.02 and 0.02 µg/well, respectively.
Five hours after transfection cells were fed with 250 µl/
well of serum-free medium containing various concentra-
tions (0–100 µM) of CLA (either the c9, t11 isomer or t10,
c12 isomer prepared in 0.1% DMSO). Cell lysates were
prepared after 46 hours using 100 µl 1 × passive lysis
buffer (Promega) per well. Firefly and renilla luciferase
activities were measured using a Dual Luciferase Assay kit
(Promega), as described by the manufacturers.
Measurements were performed on an MLX microtitre
plate luminometer (Dynex). For the PPARα assay Cos-7
cells were plated in 24-well plates at a density of 0.5 × 105
cells/well. Cells were transfected in serum-free medium
with pPPRE3TK-luc, pRLTK, pRSV/hRXRα and pcDNA3/
hPPARα at concentrations of 0.4, 0.04, 0.03 and 0.03 µg/
well, respectively. Five hours after transfection DMEM
supplemented with 2 mM L-glutamine and 20% SBCS
(charcoal-stripped bovine calf serum, Sigma) was added
to the cells. Following 18 hours incubation at 37°C/5%
CO2  the medium was removed and replaced with
medium (DMEM supplemented with 2 mM L-glutamine
and 10% SBCS) containing various concentrations (0-100
µM) of CLA enriched to 85% with the c9, t11 isomer or
81% with the t10, c12 isomer prepared in 0.1% DMSO.
After 24 hours of treatment cell lysates were prepared and
luciferase activity measured as described above.
Statistics
Data were analysed by one-way analysis of variance fol-
lowed by LSD test with the sunflower oil treatment as the
control. Means are of 6 values with SEM.
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